AIKI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 8.60%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

AIkido Pharma Insider Trading History Chart

AIkido Pharma Share Price & Price History

^$4.76

▼ -0.03 (-0.63%)

As of 04/28/2025 01:00 AM ET

Days: 30 | 90 | 365

AIkido Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/19/2022	Kyle Michael Wool	Director	Buy	5,000	$3.59	$17,950.00	266,792
12/15/2022	Kyle Michael Wool	Director	Buy	5,000	$3.69	$18,450.00	280,322
12/14/2022	Anthony Hayes	CEO	Buy	4,500	$3.69	$16,605.00	176,681
12/12/2022	Anthony Hayes	CEO	Buy	5,000	$3.62	$18,100.00	167,181
12/9/2022	Anthony Hayes	CEO	Buy	5,000	$3.68	$18,400.00	162,181
12/7/2022	Anthony Hayes	CEO	Buy	5,000	$3.48	$17,400.00	152,181
9/16/2022	Kyle Michael Wool	Director	Buy	3,559	$6.54	$23,275.86	230,281
9/14/2022	Soo Yu	Director	Buy	1,477	$6.12	$9,039.24	83,701
9/12/2022	Anthony Hayes	CEO	Buy	38,208	$6.33	$241,856.64	122,224
9/12/2022	Soo Yu	Director	Buy	44,895	$6.33	$284,185.35	52,895

SEC Filings (Institutional Ownership Changes) for AIkido Pharma (NASDAQ:AIKI)

10.88% of AIkido Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

AIkido Pharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
10/11/2022	Equitec Proprietary Markets LLC	18,800	$0.13M	0.0%	-70.3%	0.358%
7/18/2022	Equitec Proprietary Markets LLC	63,277	$0.37M	0.1%	-78.7%	1.205%
4/22/2022	Equitec Proprietary Markets LLC	297,765	$0.13M	0.0%	N/A	0.333%
11/15/2021	GSA Capital Partners LLP	151,591	$0.13M	0.0%	-50.6%	0.169%
10/26/2021	Game Plan Financial Advisors LLC	40,000	$33K	0.0%	N/A	0.045%
8/17/2021	Millennium Management LLC	853,211	$0.82M	0.0%	N/A	0.951%
8/16/2021	State Street Corp	317,314	$0.30M	0.0%	N/A	0.354%
8/16/2021	Goldman Sachs Group Inc.	216,203	$0.21M	0.0%	N/A	0.241%
8/13/2021	Renaissance Technologies LLC	913,373	$0.87M	0.0%	N/A	1.020%
8/13/2021	Geode Capital Management LLC	696,056	$0.67M	0.0%	+13.1%	0.777%
8/13/2021	Vanguard Group Inc.	4,136,875	$3.96M	0.0%	-4.5%	4.621%
8/5/2021	GSA Capital Partners LLP	306,931	$0.29M	0.0%	N/A	0.343%
5/19/2021	Virtu Financial LLC	195,885	$0.22M	0.0%	+121.8%	0.219%
5/18/2021	Citadel Advisors LLC	346,382	$0.40M	0.0%	+310.2%	0.387%
5/13/2021	Bank of New York Mellon Corp	44,191	$50K	0.0%	N/A	0.049%
5/12/2021	Northern Trust Corp	150,654	$0.17M	0.0%	+417.6%	0.169%
5/12/2021	Geode Capital Management LLC	615,177	$0.70M	0.0%	+345.0%	0.692%
5/7/2021	BlackRock Inc.	1,542,219	$1.76M	0.0%	+2,753,862.5%	1.735%

Data available starting January 2016

See Full Table

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Today's Range

Now: $4.76

$4.43

$4.89

50 Day Range

MA: $5.33

$3.37

$11.62

52 Week Range

Now: $4.76

$3.31

$11.48

Volume

185,568 shs

Average Volume

79,326 shs

Market Capitalization

$26.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93